Patent ID: 8664388
Filing Date: 2014-03-04
Classification: A61P,C07D

Abstract:
1. A method for the treatment of a disease and/or condition wherein the inhibition of the cleavage of APP (Amyloid Precursor Protein) mediated by β-secretase is of therapeutic benefit, wherein the disease or condition is Alzheimer's disease, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula 1, wherein A is selected from the group GA.1 consisting of a C wherein the above-mentioned members of the group GA.1 may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, HO—, NC—, O R 1 is selected from the group GR1.1 consisting of H—, HO—, methyl-, ethyl, F R 2 is selected from the group GR2.1 consisting of H—, fluorine, chlorine, bromine, HO—, NC—, O wherein the above-mentioned members of the group GR2.1 may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, HO—, NC—, O R 3 is selected from the group GR3.1 consisting of H—, fluorine, chlorine, bromine, HO—, NC—, F wherein the above-mentioned members of the group GR3.1 may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, HO—, NC—, O R 4 is selected from the group GR4.1 consisting of H—, fluorine, NC—, F wherein the above-mentioned members of the group GR4.1 may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, HO—, NC—, O R 5 is selected from the group GR5.1 consisting of R R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are selected from the group GR6/11.1 consisting of H—, F wherein, if R wherein the above-mentioned aryl of group GR6/11.S1 may optionally be substituted independently of one another by one or more substituents selected from group consisting of fluorine, chlorine, bromine, NC—, F R 12 is selected from the group GR12.1 consisting of F wherein the above-mentioned members of the group GR12.1 may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, R R 13 is selected from the group GR13.1 consisting of H—, F wherein two C R 14 is selected from the group GR14.1 consisting of H—, F wherein the above-mentioned members of the group GR14.1 may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, HO—, NC—, O or a pharmaceutically acceptable salt thereof.